Anixa leverages partnerships with world-renowned research institutions like Moffitt Cancer Center and Cleveland Clinic to advance its programs, creating a capital-efficient development model. The company focuses on addressing critical unmet needs in oncology through novel mechanisms using "retired" protein targets that differentiate it in the competitive immunotherapy space.
Cyborg Score Rationale
Recent Phase 1 ovarian cancer CAR-T data shows multiple patients substantially exceeding expected survival with no dose-limiting toxicities, supporting escalation to doses up to 100x higher. The company has secured key regulatory approvals and achieved analyst consensus of Strong Buy with significant upside targets, though pre-revenue status introduces execution risk.
Top Insights
Achieved ovarian cancer CAR-T dose escalation approval following Phase 1 data showing multiple patients with substantially extended survival and no dose-limiting toxicities (February 2026).
Breast cancer vaccine Phase 1 data demonstrates 100% immune response rate with 75% of women showing robust protocol-defined response.
Ovarian cancer therapy liraltagene autoleucel received WHO International Nonproprietary Name assignment, a key step toward commercial recognition.
Operating lean with 4 employees as of March 1, 2026, leveraging partner institutions to minimize overhead while advancing clinical programs.
Named Competitors
CAR-T Cell Therapy — Leading CAR-T developer with marketed therapies and broader oncology franchise
CAR-T Cell Therapy — Established CAR-T player with approved therapies and extensive clinical pipeline
Cancer Vaccines — Developing personalized neoantigen cancer vaccines with regulatory approvals
Recent Developments
(February 2026) Ovarian cancer CAR-T trial cleared for major dose escalation with encouraging patient survival outcomes
(2025) Breast cancer vaccine IND transfer completed to Anixa from Cleveland Clinic
(2025) US Adopted Names Council approval secured for CAR-T therapy liraltagene autoleucel
Open the full interactive Anixa Biosciences, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.